Methotrexate

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Pharmacologic therapy for pediatric inflammatory bowel disease (IBD) can consist of topical therapies as well as those therapies that exert a direct effect on the host immune system. Traditionally, thiopurines have been the first line immunomodulatory agents used to treat pediatric IBD. Increasing awareness of rare but potentially life-threatening malignancies that have been associated with thiopurine use as well as cases of intolerance or lack of response to thiopurine agents has served to promote increasing utilization of another immunomodulator, methotrexate. Given once a week, either parenterally or orally, methotrexate has demonstrated efficacy in pediatric Crohn' disease with less proven efficacy in pediatric ulcerative colitis.

Original languageEnglish
Title of host publicationPediatric Inflammatory Bowel Disease, Second Edition
PublisherSpringer New York
Pages339-343
Number of pages5
ISBN (Electronic)9781461450610
ISBN (Print)9781461450603
DOIs
StatePublished - 1 Jan 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Methotrexate'. Together they form a unique fingerprint.

Cite this